| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 32.7 | 27.9 | 34.4 |
| Other income | 0.3 | 0.0 | 0.0 |
| Total income | 33.0 | 27.9 | 34.4 |
| Profit before exceptional items & tax | 4.4 | 5.2 | 6.0 |
| Profit before tax | 4.3 | 5.2 | 6.0 |
| Net profit | 2.7 | 4.2 | 4.0 |
| Operating margin | 13.0% | 18.6% | 17.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -32.50% |
|---|---|
| Net profit, quarter on quarter | -35.70% |
| Revenue, year on year | -4.90% |
NSE results filing, NSE: CURIS. Figures extracted from the filing.
Curis Lifesciences Ltd: key numbers
- Share price
- ₹202.00
- Market cap
- ₹163.3 Cr
- Revenue (annual)
- ₹60.63 Cr
- Net profit (annual)
- ₹6.92 Cr
- P/E (TTM)
- 23.6×Sector 47.4×
- Promoter holding
- 68.03%
- FII holding
- 1.19%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Curis Lifesciences Ltd
All →Curis Lifesciences Annual General Meeting
Curis Lifesciences filed its 10th AGM notice and FY 2025-26 Annual Report. The meeting is scheduled for September 29, 2026.
Curis Lifesciences Board Meeting Outcome
Curis Lifesciences Limited approved the Director's Report, related party transactions, and scheduled its 10th Annual General Meeting for September 29, 2026. Board outcomes were finalized.
Curis Lifesciences Management Change
Curis Lifesciences Limited announced the resignation of Mr. Nikhil Purohit as Company Secretary and Compliance Officer, effective September 3, 2026.
Curis Lifesciences Other Announcement
Curis Lifesciences Limited submitted the RTA confirmation certificate for the quarter ended June 30, 2026, as required under SEBI Regulation 74(5).
Curis Lifesciences Merger & Restructuring Worth ₹0.05 Cr
Curis Lifesciences Limited has acquired a 49.95% stake in CUROSUN PHARMACEUTICAL NIG LTD, Nigeria, for Rs. 5 Lakhs to expand its pharmaceutical market presence.
- Value
- ₹0.05 Cr
Curis Lifesciences Legal & Regulatory
Curis Lifesciences paid a Rs. 5,900 fine to NSE for delayed RPT disclosure compliance. The Board attributed the delay to technical portal errors.